Search Results - "Theriault, R.L."

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer by Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W.F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R.L., Kiesel, L., Hortobagyi, G.N., Pusztai, L., Gonzalez-Angulo, A.M.

“…We evaluated discordance in expression measurements for estrogen receptor (ER), progesterone receptor (PR), and HER2 between primary and recurrent tumors in…”
Get full text

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers by Brewster, A. M., Etzel, C., Zhou, R., Wong, Y., Edge, S., Blayney, D. W., Wilson, J., Hudis, C., Ottesen, R., Hughes, M. E., Weeks, J. C., Theriault, R. L.

“…Disparities in the receipt of adjuvant chemotherapy for early stage breast cancer is an important factor influencing mortality. We investigated whether greater…”
Get full text

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network by Etzel, C, Theriault, R.L, Hughes, M.E, Zhou, R, Brewster, A.M, Blayney, D.W, Hudis, C, Ottesen, R, Wong, Y, Edge, S, Weeks, J.C, Wilson, J

“…Disparities in the receipt of adjuvant chemotherapy for early stage breast cancer is an important factor influencing mortality. We investigated whether greater…”
Get full text

Effects of chronic hepatitis C infection on the treatment of breast cancer patients by Morrow, P.K.H., Tarrand, J.J., Taylor, S.H., Kau, S.-W. C., Theriault, R.L., Hortobagyi, G.N., Broglio, K.R., Hahn, K.M.

“…Although hepatitis C (HCV) is the most common blood-borne infection in the United States, little information exists about treatment of breast cancer in the…”
Get full text

Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up by Ibrahim, N. K., Buzdar, A. U., Asmar, L., Theriault, R. L., Hortobagyi, G. N.

“…Background: The purpose of this study was to evaluate the clinical outcome of doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients and to…”
Get full text

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results by Holmes, F. A., alero, V., Walters, R. S., Theriault, R. L., Booser, D. J., Gibbs, H., Fraschini, G., Buzdar, A. U., Willey, J., Frye, D., Asmar, L., Hortobagyi, G. N.

“…Purpose: We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I…”
Get full text

PP-8-9 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (AREDIA ®) infusion by Hortobagyi, G.N., Porter, L, Blayney, D., Theriault, R.L, Lipton, A., Gluck, S., Wheeler, H., Allan, S., Simeone, J., Seaman, J., Knight, R., Heffeman, M., Reitsma, D.

Get full text

A clinical dilemma: estrogen replacement therapy in postmenopausal women with a background of primary breast cancer by Theriault, R L, Sellin, R V

“…It is common practice to forego the prescribing of estrogen replacement therapy (ERT) for patients with a history of breast cancer. The consequences of…”
Get more information